Literature DB >> 1934235

Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.

B Dai1, Z H Chen, Q C Liu, T Wu, C Y Guo, X Z Wang, H H Fang, Y Z Xiang.   

Abstract

The duration of immunity following measles vaccination of 2882 immunized children has been investigated in a closed region of China for 15 years. A total of 1002 of the children were treated as primary immunization subjects, and 1547 as reimmunization subjects. These two cohorts were not in contact with known wild measles virus over the whole observation period, and the results obtained probably reflected the antibody responses to measles vaccine alone. The remaining 333 vaccinees came into contact with wild measles virus, and this permitted evaluation of the protective effect of the measles vaccines tested: 4 children experienced very mild clinical measles, and 329 experienced subclinical infection, including 12 who had had undetectable haemagglutination-inhibition antibodies for 9-10 years. These results indicate that the immunity induced by successful primary immunization may persist for at least 15 years. Within this period, a second dose of vaccine only induces low antibody responses which decrease rapidly to their original levels. This provides strong evidence that the immunity produced by primary immunization is long-lasting. However, there were some indications that reimmunization might produce better effects if live attenuated measles virus were used with a longer interval between doses.

Entities:  

Keywords:  Antibodies--analysis; Asia; Biology; China; Delivery Of Health Care; Developing Countries; Diseases; Eastern Asia; Evaluation; Health; Health Services; Immunity; Immunization; Immunologic Factors; Measles; Measurement; Physiology; Primary Health Care; Research Methodology; Viral Diseases

Mesh:

Substances:

Year:  1991        PMID: 1934235      PMCID: PMC2393239     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  8 in total

1.  Booster vaccination with further live attenuated measles vaccine.

Authors:  J W Bass; S B Halstead; G W Fischer; J K Podgore; W R Pearl; M Schydlower; R A Wiebe; F M Ching
Journal:  JAMA       Date:  1976-01-05       Impact factor: 56.272

2.  Long-term antibody response after measles vaccination in an isolated arctic society in Greenland.

Authors:  I R Pedersen; C H Mordhorst; T Ewald; H von Magnus
Journal:  Vaccine       Date:  1986-09       Impact factor: 3.641

3.  Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination.

Authors:  F L Black; L L Berman; M Libel; C A Reichelt; F D Pinheiro; A Travassos da Rosa; F Figueira; E Siqueira Gonzales
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

4.  Measles revaccination. Persistence and degree of antibody titer by type of immune response.

Authors:  J Deseda-Tous; J D Cherry; M J Spencer; R C Welliver; K M Boyer; J P Dudley; J M Zahradnik; P J Krause; E W Walbergh
Journal:  Am J Dis Child       Date:  1978-03

5.  Live measles vaccine: a 21 year follow up.

Authors:  C Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-04

6.  Measles immunity after revaccination: results in children vaccinated before 10 months of age.

Authors:  C C Linnemann; M S Dine; G A Roselle; P A Askey
Journal:  Pediatrics       Date:  1982-03       Impact factor: 7.124

7.  Further-attenuated measles vaccine: characteristics and use.

Authors:  S Krugman
Journal:  Rev Infect Dis       Date:  1983 May-Jun

8.  A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.

Authors:  S Isomura; T Morishima; K Nishikawa; N Hanada; M Rahman; M Terashima; S Kido; S Ueda; M Takahashi
Journal:  Biken J       Date:  1986-03
  8 in total
  18 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

2.  Backward bifurcations and multiple equilibria in epidemic models with structured immunity.

Authors:  Timothy C Reluga; Jan Medlock; Alan S Perelson
Journal:  J Theor Biol       Date:  2008-01-26       Impact factor: 2.691

3.  Measles epidemic from 1951 to 2012 and vaccine effectiveness in Guangzhou, southern China.

Authors:  Zhicong Yang; Jianxiong Xu; Ming Wang; Biao Di; Huifeng Tan; Qing He; Yanshan Cai; Jianhua Liang; Wensui Hu; Zhiqiang Dong; Yunqing Yang; Chuanxi Fu
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

4.  Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.

Authors:  Yuemei Hu; Gang Zeng; Kai Chu; Jing Zhang; Weixiao Han; Ying Zhang; Jing Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2018-04-11       Impact factor: 3.452

5.  Measles vaccination of young infants in China: A cost-effectiveness analysis.

Authors:  Cara Bess Janusz; Abram L Wagner; Nina B Masters; Yaxing Ding; Ying Zhang; David W Hutton; Matthew L Boulton
Journal:  Vaccine       Date:  2020-05-22       Impact factor: 3.641

6.  Epidemiology of measles in Taiwan: dynamics of transmission and timeliness of reporting during an epidemic in 1988-9.

Authors:  M S Lee; C C King; C J Chen; S Y Yang; M S Ho
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

7.  Measles vaccine: a 27-year follow-up.

Authors:  M E Ramsay; D Moffatt; M O'Connor
Journal:  Epidemiol Infect       Date:  1994-04       Impact factor: 2.451

8.  Vaccination coverage and timeliness in three South African areas: a prospective study.

Authors:  Lars T Fadnes; Debra Jackson; Ingunn M S Engebretsen; Wanga Zembe; David Sanders; Halvor Sommerfelt; Thorkild Tylleskär
Journal:  BMC Public Health       Date:  2011-05-27       Impact factor: 3.295

9.  Measles seroprevalence among healthcare workers in South Korea during the post-elimination period.

Authors:  Seung Beom Han; Sun Hee Park; Yunmi Yi; Seul Ki Ji; So Hee Jang; Min Hee Park; Ji Eun Lee; Hye Sook Jeong; Soyoung Shin
Journal:  Hum Vaccin Immunother       Date:  2021-03-09       Impact factor: 3.452

10.  Following in the footsteps of smallpox: can we achieve the global eradication of measles?

Authors:  Oliver WC Morgan
Journal:  BMC Int Health Hum Rights       Date:  2004-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.